Ascendia

  MARKET NEWS

Acer Therapeutics Announces Full Enrollment of Phase 2a Trial for Treatment of Moderate-to- Severe Vasomotor Symptoms Associated With Menopause
Sermonix Pharmaceuticals & Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial
Vaxxas Initiates Phase 1 Clinical Study of First Needle-Free, Inactivated Seasonal Influenza Vaccine Quadrivalent Delivered Using High-Density Microarray Patch
EuMentis Therapeutics Inc. Receives $3-Million Award from US DoD to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury
Bayer Announces First Patients Enrolled in Global Phase 3 Studies for Investigational Oral FXIa Inhibitor Asundexian
Syneos Health & Haystack Health Partner to Accelerate Clinical Trials With AI

  FEATURED EDITORIAL

  COMPANY PROFILE

Specializing in lentiviral and retroviral vectors, Genezen offers early-phase process development, GMP vector production, analytical testing services and assay development. Leveraging the expansive knowledge and experience of its team, Genezen accelerates cell and gene therapies to commercialization and helps deliver life-changing therapeutics to patients. Founded in 2014, the company strives to make viral vector production accessible to early-stage, growth-oriented companies and established industry leaders. Genezen operates out of a 75,000-square-foot, state-of-the-art, cGMP-compliant lentiviral and retroviral vector production facility. Situated in the fast-growing life sciences hub of Indianapolis, the laboratory is the second phase of a larger cGMP-compliant lentiviral and retroviral vector production facility, which will house multiple cGMP production suites with capabilities for host cell expansion and banking and viral vector production. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients With Early Alzheimer’s Disease

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients With Early Alzheimer’s Disease

Acumen Pharmaceuticals, Inc. recently announced the completion of enrollment in its Phase 1 INTERCEPT-AD trial of ACU193 in patients with early Alzheimer’s disease…..

Quotient Sciences Expands Formulation Development Capabilities to Further Accelerate Drug Development Timelines

Quotient Sciences Expands Formulation Development Capabilities to Further Accelerate Drug Development Timelines

Company increases laboratory capacity to meet customer demand for fully integrated drug development capabilities….

Gerresheimer & Corning Announce Joint Venture to Meet Growing Demand for Velocity® Vials, Accelerating the Delivery of Life-Saving Treatments

Gerresheimer & Corning Announce Joint Venture to Meet Growing Demand for Velocity® Vials, Accelerating the Delivery of Life-Saving Treatments

The partnership will combine Gerresheimer’s extensive glass converting expertise with Corning’s Velocity® Vial technology platform, helping set a new standard for the industry….

Pantherna & Evaxion Announce Promising Preclinical mRNA Vaccine Data

Pantherna & Evaxion Announce Promising Preclinical mRNA Vaccine Data

Evaxion Biotech A/S and Pantherna Therapeutics GmbH recently announced preclinical proof of concept for the combination of the two companies’ key….

Nectin Therapeutics to Collaborate With Merck on Clinical Trial of Anti-PVR Antibody in Combination with KEYTRUDA in Patients With Locally Advanced & Metastatic Solid Tumors

Nectin Therapeutics to Collaborate With Merck on Clinical Trial of Anti-PVR Antibody in Combination with KEYTRUDA in Patients With Locally Advanced & Metastatic Solid Tumors

Nectin Therapeutics Ltd. recently announced it has entered into a clinical trial collaboration agreement with Merck. Under this collaboration, Nectin will evaluate the safety, tolerability, and antitumor activity of its novel….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening

WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening

Abstract: A team of bioavailability experts at Catalent used the in-house bioavailability enhancement platform, OptiForm® Solution Suite, to optimize and develop Phase 1 clinical formulation within a short timeline. Catalent’s global supply chain expertise was utilized for packaging and distributing …

WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)

WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)

Abstract: Catalent’s proprietary Zydis® ODT platform is backed by a large number of clinical studies. This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets. Factors addressed include bioavailability, safety, side effects, speed/pharmacokinetics, variability, …

WHITEPAPER - Maintaining Sustainable Business Practices During the Energy & Supply Crisis

WHITEPAPER - Maintaining Sustainable Business Practices During the Energy & Supply Crisis

By: Thomas Otto, Managing Director, Vetter

As we come to the end of another year, our global economy faces many significant challenges. Recently, a colleague asked me, “As a biopharma executive, which of today’s major issues are the ones that …

WHITEPAPER WORKSHOP - Soft Mist Inhalers

WHITEPAPER WORKSHOP - Soft Mist Inhalers

Soft mist inhalers (SMIs) are a versatile technology suitable for the delivery of both small and complex large molecules, optimising lung deposition whilst minimising oropharyngeal deposition.

The Resyca® SMI is a joint venture between Recipharm and Medspray that harnesses …

WHITEPAPER - Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development

WHITEPAPER - Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development

Manufacturing Phase 1 clinical material in as little as 12–16 months

Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more molecules in development fall under …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 22 – ODT/Fast Dissolve
March 1 – Drug Delivery